Skip to main content
SpringerLink
Log in

Drugs and Brain Death

  • Review Articles
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Brain death protocols facilitate early recognition of death in patients on life support systems. When the clinical situation has deteriorated to a level where brain death is to be considered, it is essential that the effects of drugs be excluded. Most centrally acting drugs depress respiration and would be expected to affect apnoea testing of brain stem function. However, the pharmacodynamic and pharmacokinetic properties of drugs are altered when patients are critically ill, so projections made from data derived from less ill patients or normal volunteers are inappropriate. The entry of drugs into the brain is also altered in some disease states, but there are few data relating to the effects of central depressant drugs in the situation of a disrupted blood-brain barrier or brain damage. Drug screens can assist in determining whether drugs are present, but correct interpretation of the results depends on close liaison between the clinical and laboratory staff. It is in the patient’s interests to avoid termination of life support if any centrally active drug is present, unless there are other categorical factors consistent with irreversible brain death, such as demonstrated lack of cerebral blood flow.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hutchesson P, Watson B, Schockett W, editors. The All England Law Reports. Airedale NHS Trust vs Bland. 1993 Mar; Pt 10: 821

  2. Brierley JB, Adams JH, Graham DI, et al. Neocortical death after cardiac arrest. Lancet 1971; ii: 560–5

    Google Scholar 

  3. Ad Hoc Committee of the Harvard Medical School to Examine the Definition of Brain Death. A definition of irreversible coma. JAMA 1968; 205(6): 337–40

    Article  Google Scholar 

  4. Diagnosis of brainv death. Statement by the honorary secretary of the Conference of Medical Royal Colleges and their Faculties in the United Kingdom. BMJ 1976; 2: 1187–8

    Article  Google Scholar 

  5. Special Communication. Guidelines for the determination of Death. JAMA 1981; 246(19): 2185–6

    Google Scholar 

  6. Searle J, Collins C. A brain-death protocol. Lancet 1980; i: 641–3

    Article  Google Scholar 

  7. Black PM. Brain death: part I. N Engl J Med 1978; 299(8): 338–44

    Article  PubMed  CAS  Google Scholar 

  8. Black PM. Brain death: part II. N Engl J Med 1978; 299(8): 393–401

    Article  PubMed  CAS  Google Scholar 

  9. Pallis C. ABC of brain stem death: reappraising death. BMJ (Clin Res Ed) 1982; 285: 1409–12

    Article  CAS  Google Scholar 

  10. Pallis C. ABC of brain stem death: from brain death to brain stem death. BMJ 1982; 285: 1487–90

    Article  PubMed  CAS  Google Scholar 

  11. Pallis C. ABC of brain stem death: diagnosis of brain stem death −1. BMJ 1982; 285: 1558–60

    Article  PubMed  CAS  Google Scholar 

  12. Pallis C. ABC of brain stem death: diagnosis of brain stem death −2. BMJ 1982; 285: 1643–4

    Google Scholar 

  13. Pallis C. ABC of brain stem death: pitfalls and safeguards. BMJ 1982; 285: 1720–2

    Article  PubMed  CAS  Google Scholar 

  14. Australian and New Zealand Intensive Care Society. Statement and guidelines on brain death and organ donation. Carlton (Vic): Australian and New Zealand Intensive Care Society, 1993

    Google Scholar 

  15. Dobb GJ, Weekes JW. Clinical confirmation of brain death. Anaesth Intensive Care 1995; 23: 37–43

    PubMed  CAS  Google Scholar 

  16. Osternol J. Testing for drugs of abuse: pharmacokinetic considerations for cocaine in urine. Clin Pharmacokinet 1993; 24(5): 255–61

    Google Scholar 

  17. Heinemeyer G. Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure. Clin Pharmacokinet 1987; 13: 1–25

    Article  PubMed  CAS  Google Scholar 

  18. Bodenham A, Shelly M, Park G. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin Pharmacokinet 1988; 14: 347–73

    Article  PubMed  CAS  Google Scholar 

  19. Bass J, Miles MV, Tennison MB, et al. Effects of enterai tube feeding on the absorption and pharmacokinetic profile of carbamazepine suspension. Epilepsia 1989; 30: 364–9

    Article  PubMed  CAS  Google Scholar 

  20. Randall C, Tett S. Phenytoin pharmacokinetics after intravenous administration to patients receiving enterai tube feeding. Pharm World Sci 1994; 16(4) 217–24

    Article  Google Scholar 

  21. Cumming JF. The effect of arterial oxygen tension on antipyrine half-time in plasma. Clin Pharmacol Ther 1976; 19: 468–71

    CAS  Google Scholar 

  22. Perkins MW, Dasta JF, DeHaven B. Physiologic implications of mechanical ventilation on pharmacokinetics. Ann Pharmacother 1989; 23: 316–23

    CAS  Google Scholar 

  23. Milne RW, Nation RL, Somogyi AA, et al. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive care patients. Br J Clin Pharmacol 1992; 34: 53–9

    Article  PubMed  CAS  Google Scholar 

  24. Boucher BA, Khul DA, Fabian TC, et al. The effect of neurotrauma on hepatic drug clearance. Clin Pharmacol Ther 1991; 5(1): 487–97

    Article  Google Scholar 

  25. De Boer AG, Breimer DD. The blood-brain barrier: implications for drug delivery to the brain. J R Coll Physicians Lond 1994; 28(6): 502–6

    PubMed  Google Scholar 

  26. Bradbury MWB. The blood-brain barrier. Exp Physiol 1993; 78: 453–72

    PubMed  CAS  Google Scholar 

  27. Reese TS, Karnovsky MJ. Fine structural localisation of a blood-brain barrier to exogenous peroxidase. J Cell Biol 1967; 34: 207–17

    Article  PubMed  CAS  Google Scholar 

  28. Bonati M, Kanto J, Tognoni G. Clinical pharmacokinetics of cerebrospinal fluid. Clin Pharmacokinet 1982; 7: 312–35

    Article  PubMed  CAS  Google Scholar 

  29. Brodie B, Kurtz H, Schanker L. The importance of dissociation constant and lipid solubility in influencing the passage of drugs into the cerebrospinal fluid. J Pharmacol Exp Ther 1960; 130: 20–5

    PubMed  CAS  Google Scholar 

  30. Crone C. The permeability of brain capillaries to non-electrolytes. Acta Physiol Scand 1965; 64: 407–17

    Article  PubMed  CAS  Google Scholar 

  31. Van Bree JBM, DeBoer AG, Danhof M, et al. Characterisation of an ‘in vitro’ blood brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J Pharmacol Exp Ther 1988; 247(3): 1233–9

    PubMed  Google Scholar 

  32. Joo F, Klatzo I. Role of cerebral endothelium in brain oedema. Neurol Res 1989; 11: 67–75

    PubMed  CAS  Google Scholar 

  33. Bullock R, Fujisawa H. The role of glutamate antagonists for the treatment of CNS injury. J Neurotrauma 1992; 9 Suppl. 2: 443–61

    Google Scholar 

  34. Benzel EC, Gross CD, Hadden TA, et al. The apnea test for determination of brain death. J Neurosurg 1989; 71: 191–4

    Article  PubMed  CAS  Google Scholar 

  35. Berger AJ, Mitchell RA, Severingham JW. Regulation of respiration: part I. N Engl J Med 1977; 297(2): 92–7

    Article  PubMed  CAS  Google Scholar 

  36. Berger AJ, Mitchell RA, Severingham JW. Regulation of respiration: part II. N Engl J Med 1977; 297(3): 138–43

    Article  PubMed  CAS  Google Scholar 

  37. Berger AJ, Mitchell RA, Severingham JW. Regulation of respiration: part III. N Engl J Med 1977; 297(4): 194–201

    Article  PubMed  CAS  Google Scholar 

  38. Nunn JF. Control of breathing. Nunn’s applied respiratory physiology. 4th ed. London: Butterworth, 1993 90–116

    Google Scholar 

  39. Cohn MA. Hypnotics and the control of breathing: a review. Br J Clin Pharm 1983: 16 Suppl.: 245–50

    Article  CAS  Google Scholar 

  40. Olson KR, Pentel PR, Kelley MT. Physical assessment and differential diagnosis of the poisoned patient. Med Toxicol 1987; 2: 52–81

    PubMed  CAS  Google Scholar 

  41. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurological disorders. N Engl J Med 1994; 330(9): 613–20

    Article  PubMed  CAS  Google Scholar 

  42. Mandema JW, Danhof M. Electroencephalogram effect measures and relationship between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin Pharmacokinet 1992; 23(3): 191–215

    Article  PubMed  CAS  Google Scholar 

  43. Powner DJ. Drug associated isoelectric EEGs: a hazard in braindeath certification. JAMA 1976; 236: 1123

    Article  PubMed  CAS  Google Scholar 

  44. Setzer N. Brain death: physiologic definitions. Crit Care Clin 1985; 1(2): 375–96

    PubMed  CAS  Google Scholar 

  45. Taylor MJ, Houston BD, Lowry NJ. Recovery of auditory brainstem responses after a severe hypoxic ischaemic insult. N Engl J Med 1983; 309: 1169–70

    Article  PubMed  CAS  Google Scholar 

  46. Levine SR, Brust JCM, Furtell N, et al. Cerebrovascular complications of the use of the ‘crack’ form of alkaloidal cocaine. N Engl J Med. 1990; 323: 699–704

    Article  PubMed  CAS  Google Scholar 

  47. Bucthal F, Svensmark O, Schiller PJ. Clinical and electroen-cephalographic correlation with serum levels of diphenylhydantoin. Arch Neurol 1960; 2: 624–30

    Article  Google Scholar 

  48. Lund L. Anticonvulsant effect of diphenylhydantoin relative to plasma levels. Arch Neurol 1974; 31(5): 289–94

    Article  PubMed  CAS  Google Scholar 

  49. Ingelfinger JA, Isakson G, Shine D, et al. Reliability of the toxic screen in overdose. Clin Pharmacol Ther 1981; 29(5) 570–95

    Article  PubMed  CAS  Google Scholar 

  50. Spiechler VR, O’Donnell CM, Gokhale DV. Confirmation and certainty in toxicology screening. Clin Chem 1988; 34(8) 1535–9

    Google Scholar 

  51. Op de Coul AAW, Lambregts PCLA, Koeman J, et al. Neuromuscular complications in patients given Pavulon® (pancuronium bromide) during artificial ventilation. Clin Neurol Neurosurg 1985; 87(1): 17–22

    Article  PubMed  CAS  Google Scholar 

  52. Belaesky M, Kalwans HI. Prolonged neuromuscular blockade with pancuronium bromide in a young healthy woman. Anaesthesiology 1971; 40(3): 295–6

    Article  Google Scholar 

  53. Segredo V, Caldwell JE, Marthay MA, et al. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992; 327: 524–8

    Article  PubMed  CAS  Google Scholar 

  54. Tyson RN. Simulation of cerebral death by succinylcholine sensitivity. Arch Neurol 1974; 30: 409–11

    Article  PubMed  CAS  Google Scholar 

  55. Shapiro HM. Barbiturates in brain ischaemia. Br J Anaesth 1985; 57: 82–95

    Article  PubMed  CAS  Google Scholar 

  56. Scatton B, Carter C, Benavides J, et al. N-Methyl-D-Aspartate receptor antagonists: a novel therapeutic perspective for the treatment of ischaemic brain injury. Cerebrovasc Dis 1991; 1: 121–35

    Article  Google Scholar 

  57. Fitzpatrick AJ, Crawford M, Allan RM, et al. Aconite poisoning managed with a ventricular assist device. Anaesth Intensive Care 1994; 22: 714–7

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology and Toxicology, St Vincent’s Hospital, Sydney, New South Wales, Australia

    Michael Kennedy

  2. Intensive Care Unit, Sutherland Hospital, Caringbah, New South Wales, Australia

    Neil Kiloh

Authors
  1. Michael Kennedy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neil Kiloh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kennedy, M., Kiloh, N. Drugs and Brain Death. Drug-Safety 14, 171–180 (1996). https://doi.org/10.2165/00002018-199614030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199614030-00004

Keywords

Search

Navigation